Krishna Iyer, MD, PhD
Clinical FellowDownloadHi-Res Photo
About
Copy Link
Titles
Clinical Fellow
Appointments
Education & Training
- Clinical Research Fellow
- Yale School of Medicine (2024)
- Residency (AP/CP)
- Yale New Haven Hospital (2023)
- Post-doctoral scholar (T32)
- University of Iowa Carver College of Medicine (2019)
- Internship
- University of Pittsburgh Medical Center (2017)
- MD
- University of Iowa
- PhD
- University of Iowa, Biomedical Engineering (2016)
Research
Copy Link
Overview
Public Health Interests
Aging; Biomarkers; Cancer; Immunology
- View Lab Website
Schalper Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Krishna Iyer's published research.
Henry Rinder, MD
Joe El-Khoury, PhD, DABCC
Ronald George Hauser III, MD
Publications
2022
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. The New England Journal Of Medicine 2022, 386: 2363-2376. PMID: 35660797, PMCID: PMC9492301, DOI: 10.1056/nejmoa2201445.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDNA Mismatch RepairHumansNeoadjuvant TherapyNeoplasm StagingNeoplasms, Second PrimaryProgrammed Cell Death 1 ReceptorProspective StudiesRectal NeoplasmsRectumTreatment OutcomeConceptsAdvanced rectal cancerClinical complete responsePD-1 blockadeRectal cancerComplete responseSingle-agent PD-1 blockadeAnti-PD-1 monoclonal antibodyProspective phase 2 studyMismatch repair-deficient colorectal cancersDeath-1 blockadePrimary end pointCase of progressionEvidence of tumorPathological complete responsePhase 2 studyDigital rectal examinationDuration of responseMismatch repair deficientMagnetic resonance imagingNeoadjuvant chemotherapyUndergone surgeryAdverse eventsCheckpoint blockadeMetastatic diseaseSurgical resectionUnexpectedly low hemoglobin A1c in a patient with chronic lymphocytic leukemia
Jacobs JW, Gisriel SD, Iyer K, Hauser RG, El-Khoury JM. Unexpectedly low hemoglobin A1c in a patient with chronic lymphocytic leukemia. Clinica Chimica Acta 2022, 531: 91-93. PMID: 35351433, DOI: 10.1016/j.cca.2022.03.012.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic lymphocytic leukemiaNeoplastic lymphocytesLymphocytic leukemiaDiabetes mellitus type 2Red blood cell survivalMellitus type 2Blood cell survivalGlycated hemoglobin assaysCertain medicationsLower hemoglobinHemolytic anemiaType 2PatientsHemoglobin assayPrecise mechanismMarked numberLymphocytesLeukemiaCell survivalFurther investigationHemoglobin variantsAssaysMedicationsAnemiaEnzymatic assay
2021
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. Journal Of Thrombosis And Thrombolysis 2021, 53: 945-949. PMID: 34697688, PMCID: PMC8544916, DOI: 10.1007/s11239-021-02591-4.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPartial thromboplastin timeLupus anticoagulantFVIII inhibitorsAsymptomatic patientsFactor VIIIComprehensive hematologic evaluationLife-threatening hemorrhageTypical laboratory findingsDistinctive clinical presentationFactor VIII inhibitorsRisk of thrombosisSigns of hemorrhageSevere bleeding diathesisCoagulation factor VIIIImmunosuppressive therapyClinical presentationClinical symptomsPathologic antibodiesVIII inhibitorsLaboratory findingsHematologic evaluationUnique presentationBleeding diathesisThromboplastin timeAutoantibodies
News
Copy Link
Get In Touch
Copy Link